38 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
of safety issues. The Company intends to explore the viability of developing CT2000 as a topical agent for the relief of eye pain. A potential advantage … of drug-related skin reactions. The primary endpoint of the dose escalation trail will be safety and tolerability of the slower dose titration
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
of safety issues. The Company intends to explore the viability of developing CT2000 as a topical agent for the relief of eye pain. A potential advantage … of drug-related skin reactions. The primary endpoint of the dose escalation trail will be safety and tolerability of the slower dose titration
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
) are limited in their effectiveness and/or limited in the duration that they may be prescribed because of safety issues. The Company intends to explore … trail will be safety and tolerability of the slower dose titration; however, we will also be measuring blood concentrations of CC8464, which
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
target selectivity and a favorable in vitro cardiac safety profile (in vitro electrophysiology experiments where we measured differences between cells … study investigating safety, tolerability and pharmacokinetics of single and multiple ascending doses of CC8464 in healthy volunteers has been completed
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
target selectivity and a favorable in vitro cardiac safety profile (in vitro electrophysiology experiments where we measured differences between cells … study investigating safety, tolerability and pharmacokinetics of single and multiple ascending doses of CC8464 in healthy volunteers has been completed
10-K
z48 3ltel9kss
16 Apr 24
Annual report
4:48pm
8-K
EX-99.1
5gcovv djssxy19w3j
9 Apr 24
Chromocell Issues Letter to Stockholders from Chief Executive Officer
8:30am
8-K
EX-99.1
60vkxv1
13 Mar 24
Regulation FD Disclosure
8:00am
8-K
EX-1.1
cqq8n1
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
8-K
EX-3.2
6dc3 qhy118f
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
424B4
zn95mpuwy v1
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
z3ga9v82
20 Feb 24
Prospectus supplement with pricing info
5:28pm
FWP
u54ux65p9
12 Feb 24
Free writing prospectus
8:09am
FWP
b94rrimw1
6 Feb 24
Free writing prospectus
8:43pm
FWP
0t0tn31229ypd3946pns
31 Jan 24
Free writing prospectus
4:16pm